Rare neurological condition is 'important potential risk' of Pfizer's RSV vaccine, FDA says
Two people who received Pfizer's respiratory syncytial virus vaccine during a clinical trial were later diagnosed with Guillain-Barre syndrome, and the FDA has asked Pfizer to conduct a safety study if the shot is approved, according to agency documents released on February 24.
As featured on
Two people who received Pfizer's respiratory syncytial virus (RSV) vaccine during a clinical…